Table 3.
OS and PFS in different types of TP53 mutation in EGFR-mutated NSCLC patients.
| Study | Comparison | mOS (months) | mPFS (months) |
|---|---|---|---|
| Hou 2019 (34) | Missense mut vs. wt | 28 vs. 52.5 (P=0.150) | 8.4 vs.14 (P=0.068) |
| Labbé 2017 (39) | Missense mut vs. wt | P= 0.46 | P=0.04 |
| Hou 2019 (34) | Non-missense mut vs. wt | 21.2 vs. 52.5 (P=0.001) | 6.3 vs. 14 (P=0.041) |
| Yu 2021 (25) | Non-disruptive mut vs. wt | 21.73 vs. 31.6 (P<0.001) | 7.57 vs. 13 (P=0.01) |
| Hou 2019 (34) | Non-disruptive mut vs. wt | 35 vs. 52.5 (P=0.008) | 6.3 vs. 14 (P=0.028) |
| Molina-Vila 2014 (40) | Non-disruptive mut vs. wt | 17.8 vs. 28.4 (P=0.04) | 11 vs. 15 (P=0.14) |
| Jiao 2018 (41) | Non-disruptive mut vs. disruptive mut | 21 vs. 18 (P=0.69) | N/A |
| Yang 2020 (42) | Exon 4/7 vs. other mut vs. wt | 15.8 vs. 20.0 vs. 26.1 (P=0.004) | 9.4 vs. 11.0 vs. 14.5 (P=0.008) |
| Hou 2019 (34) | Exon 7 vs. wt | 14 vs. 52.5 (P=0.009) | 5 vs. 14 (P=0.002) |
| Jiao 2018 (41) | Exon5/7-9 vs. exon4/6/multiple exon mut/unknown exon mut vs. wt | 21 vs. 13 vs. 27 (P<0.001) | N/A |
| Canale2020 (43) | Exon 8 vs. other mut vs. wt | 18.53 vs. 34.8 vs. 27.3 (P=0.440) | 5.8 vs. 14.4 vs. 12.4 (P=0.002) |
N/A, No Available.